Article info

Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review
Free

Authors

  • Linda van der Tol Department of Endocrinology and Metabolism, Amsterdam Lysosome Center ‘Sphinx’, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Marije L Sminia Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Ophthalmology, Medical Center Alkmaar, Alkmaar, The Netherlands PubMed articlesGoogle scholar articles
  • Carla E M Hollak Department of Endocrinology and Metabolism, Amsterdam Lysosome Center ‘Sphinx’, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Marieke Biegstraaten Department of Endocrinology and Metabolism, Amsterdam Lysosome Center ‘Sphinx’, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Marieke Biegstraaten, Academic Medical Center, Department of Internal Medicine, Room F5-166, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; M.Biegstraaten{at}amc.uva.nl
View Full Text

Citation

van der Tol L, Sminia ML, Hollak CEM, et al
Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review

Publication history

  • Received November 20, 2014
  • Revised January 11, 2015
  • Accepted January 17, 2015
  • First published February 12, 2015.
Online issue publication 
March 22, 2016

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.